IDO1 and renal cell carcinoma: In the present study, we incorporated TAM, Treg and its co-inhibitory molecules, CD8 or CD68 coexpressing PD-1 or IDO, CD3 coexpressing PD-L1 to build a novel immune feature-based score to predict the OS of RCC patients after nephrectomy and compared this new model to the IS proposed by the SITC.